Source-grounded facts extracted from Vyome Holdings, Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vyome Holdings, Inc: Approved an amendment to decrease authorized common stock from 300,000,000 to 50,000,000 shares (effective 2026-04-24).
“On April 24, 2026, the Company filed the Certificate of Tenth Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effectuate the decrease in authorized shares.”
Vyome Holdings, Inc amended Notes Purchase and Exchange Agreement with Remus Capital Series B II, L.P. (effective 2026-02-25).
“☐ Item 1.01 Entry into a Material Definitive Agreement Notes Purchase and Exchange Agreement As previously reported, on December 17, 2025,”
Vyome Holdings, Inc entered into Notes Purchase and Exchange Agreement with Remus Capital Series B II, L.P. valued at aggregate principal amount of $5,765,000 (effective 2026-02-20).
“As of February 20, 2026, pursuant to the terms of the LOI, the Company entered into a Notes Purchase and Exchange Agreement (the “Agreement”) by and among LICH, LICH AI Inc. (the “Buyer”), a subsidiary of LICH, and Remus to effectuate the transactions contemplated by the LOI.”
Vyome Holdings, Inc engaged Kreit & Chiu CPA LLP as its auditor.
“Effective as of August 18, 2025 Kreit & Chiu CPA LLP (“Kreit & Chiu”) was appointed to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Vyome Holdings, Inc dismissed Haskell & White LLP as its auditor.
“On August 18, 2025, Haskell & White LLP (“Haskell”), was dismissed as the independent registered public accounting firm of the Company, formerly ReShape Lifesciences Inc.”
Vyome Holdings, Inc: Filed Certificate of Ninth Amendment to change corporate name to Vyome Holdings, Inc. and set board composition with six directors in three classes (effective 2025-08-15).
“a Certificate of Ninth Amendment (the “Certificate of Ninth Amendment”) with the Secretary of State of the State of Delaware to amend the Company’s Restated Certificate of Incorporation, as amended, to change its corporate name to Vyome Holdings, Inc. and set forth the Combined Company’s composition of board of directors which will be initially comprised of six directors and divided into three classes with staggered three-year terms”
Vyome Holdings, Inc: Filed Certificate of Eighth Amendment to effect 1-for-4 reverse stock split (effective 2025-08-15).
“on August 15, 2025 the Company filed a Certificate of Eighth Amendment (the “Certificate of Eighth Amendment”) with the Secretary of State of the State of Delaware to amend the Company’s Restated Certificate of Incorporation, as amended, and effected the Reverse Stock Split on August 15, 2025.”
Vyome Holdings, Inc completed a disposition involving Ninburgh Health International Limited for $2.25 million in cash (closed 2025-04-25).
“Asset Purchase Agreement, ReShape sold its assets (excluding cash) to Biorad, and Biorad assumed substantially all of ReShape’s liabilities, for an agreed upon purchase price of $2.25 million in cash, subject to adjustment based on ReShape’s actual accounts receivable and accounts payable at the closing, compared to such amounts as of March 31, 2024.”
Vyome Holdings, Inc completed an acquisition involving Vyome Therapeutics, Inc. (closed 2025-08-15).
“On August 15, 2025, Vyome Holdings, Inc. (f/k/a ReShape Lifesciences Inc.) (the “Company”) completed the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the “Merger Agreement”), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and Vyome Therapeutics, Inc. (“Vyome”).”
Gary Blackford resigned as Director at Vyome Holdings, Inc.
“Gary Blackford informed the Board of Directors (the “Board”) of ReShape Lifesciences Inc. (the “Company”) of his decision to resign from the Board and all related committees effective March 15, 2025.”
Vyome Holdings, Inc engaged Haskell & White LLP as its auditor.
“with the prior approval of the Audit Committee, the Company engaged Haskell & White LLP (“Haskell & White”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 and related interim periods.”
Vyome Holdings, Inc dismissed RSM US LLP as its auditor.
“On April 8, 2024, ReShape Lifesciences Inc. (the “Company”), with the prior approval of the Audit Committee of the Board of Directors, dismissed RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm, effective immediately.”
Vyome Holdings, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“April 9, 2024, the Company received a written notice from the Nasdaq Staff that the Company has not regained compliance with the minimum $1.00 bid price requirement. However, the Nasdaq Staff has determined that the Company is eligible for an additional 180 calendar period, or until October 7, 2024, to regain compliance. If at any time during this period the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq Staff will provide the Company with a written confirmation of compliance and the matter will be closed. I”
Vyome Holdings, Inc reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $8.7 million. Guidance reaffirmed.
“Revenue totaled $8.7 million for the year ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.